Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
trametinib (413) 413
science & technology (300) 300
life sciences & biomedicine (296) 296
dabrafenib (212) 212
oncology (200) 200
melanoma (189) 189
humans (184) 184
mutation (107) 107
vemurafenib (99) 99
braf (91) 91
melanoma - drug therapy (87) 87
female (75) 75
mek inhibitor (71) 71
male (65) 65
mek (65) 65
proto-oncogene proteins b-raf - genetics (61) 61
middle aged (59) 59
metastasis (57) 57
cancer (55) 55
kinases (52) 52
protein kinase inhibitors - therapeutic use (52) 52
pyridones - administration & dosage (50) 50
pyrimidinones - administration & dosage (50) 50
antineoplastic agents - therapeutic use (49) 49
pharmacology & pharmacy (49) 49
skin neoplasms - drug therapy (49) 49
pyridones - therapeutic use (48) 48
pyrimidinones - therapeutic use (48) 48
aged (47) 47
tumors (46) 46
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
patients (45) 45
chemotherapy (44) 44
neoplasms (44) 44
animals (43) 43
care and treatment (43) 43
ipilimumab (43) 43
melanoma - pathology (42) 42
dermatology (41) 41
adult (40) 40
immunotherapy (39) 39
mek inhibitors (39) 39
melanoma - genetics (39) 39
targeted therapy (39) 39
treatment outcome (39) 39
proto-oncogene proteins b-raf - antagonists & inhibitors (38) 38
pyridones - adverse effects (38) 38
pyrimidinones - adverse effects (38) 38
protein kinase inhibitors - pharmacology (35) 35
skin neoplasms - pathology (35) 35
cobimetinib (34) 34
antineoplastic agents - pharmacology (33) 33
drug therapy (33) 33
imidazoles - administration & dosage (32) 32
oximes - administration & dosage (32) 32
map kinase (31) 31
pyridones - pharmacology (31) 31
pyrimidinones - pharmacology (31) 31
cancer therapies (30) 30
cell biology (30) 30
nivolumab (30) 30
research (30) 30
cell line, tumor (29) 29
health aspects (29) 29
neoplasms. tumors. oncology. including cancer and carcinogens (29) 29
proteins (29) 29
medicine & public health (28) 28
antineoplastic agents (27) 27
antineoplastic combined chemotherapy protocols - adverse effects (27) 27
genetic aspects (27) 27
braf inhibitor (26) 26
gene mutations (26) 26
pembrolizumab (26) 26
case report (25) 25
clinical trials (25) 25
development and progression (24) 24
phosphorylation (24) 24
protein kinase inhibitors - adverse effects (24) 24
skin neoplasms - genetics (24) 24
antimitotic agents (23) 23
imidazoles - adverse effects (23) 23
oximes - adverse effects (23) 23
map kinase kinase 1 - antagonists & inhibitors (22) 22
metastatic melanoma (22) 22
mitogen-activated protein kinase kinases - antagonists & inhibitors (22) 22
aged, 80 and over (21) 21
antineoplastic agents - adverse effects (21) 21
molecular targeted therapy (21) 21
analysis (20) 20
map kinase signaling system - drug effects (20) 20
mice (20) 20
mapk (19) 19
neoplasms - drug therapy (19) 19
braf mutation (18) 18
imidazoles - therapeutic use (18) 18
medicine, research & experimental (18) 18
melanoma - secondary (18) 18
metastases (18) 18
nras (18) 18
research & experimental medicine (18) 18
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (428) 428
Spanish (3) 3
German (2) 2
Russian (2) 2
Czech (1) 1
French (1) 1
Japanese (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
by Long, G.V and Flaherty, K.T and Stroyakovskiy, D and Gogas, H and Levchenko, E and de Braud, F and Larkin, J and Garbe, C and Jouary, T and Hauschild, A and Chiarion-Sileni, V and Lebbe, C and Mandalà, M and Millward, M and Arance, A and Bondarenko, I and Haanen, J.B.A.G and Hansson, J and Utikal, J and Ferraresi, V and Mohr, P and Probachai, V and Schadendorf, D and Nathan, P and Robert, C and Ribas, A and Davies, M.A and Lane, S.R and Legos, J.J and Mookerjee, B and Grob, J-J
Annals of oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
trametinib | melanoma | durable outcomes | BRAF | metastatic | dabrafenib | Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
by Johnson, Douglas B and Zhao, Fengmin and Noel, Marcus and Riely, Gregory J and Mitchell, Edith P and Wright, John J and Chen, Helen X and Gray, Robert J and Li, Shuli and McShane, Lisa M and Rubinstein, Larry V and Patton, David and Williams, P. Mickey and Hamilton, Stanly R and Conley, Barbara A and Arteaga, Carlos L and Harris, Lyndsay N and O'Dwyer, Peter J and Chen, Alice P and Flaherty, Keith T
Clinical cancer research, ISSN 1078-0432, 04/2020, Volume 26, Issue 8, pp. 1812 - 1819
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus | genomics | MEK | BRAF | Trametinib | MATCH | fusions
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text AML-331: Clinical Outcomes among Patients with Myeloid Malignancies and Mitogen-activated Protein Kinase (MAPK) Pathway Mutations Receiving Trametinib with or without Hypomethylating Agent (HMA)
by Kurian, Tony and Sallman, David and Komrokji, Rami and Lancet, Jeffrey and Sweet, Kendra and Talati, Chetasi and Song, Jinming and Hussaini, Mohammad and Padron, Eric
Clinical lymphoma, myeloma and leukemia, ISSN 2152-2650, 09/2020, Volume 20, pp. S204 - S204
trametinib | mitogen-activated protein kinase | AML | myeloid | decitabine | MAPK | azacitidine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH
by Ruzzolini, Jessica and Peppicelli, Silvia and Andreucci, Elena and Bianchini, Francesca and Margheri, Francesca and Laurenzana, Anna and Fibbi, Gabriella and Pimpinelli, Nicola and Calorini, Lido
Cancer letters, ISSN 0304-3835, 11/2017, Volume 408, pp. 43 - 54
Vemurafenib | BRAFV600E melanoma cells | Tumor microenvironment | Acidosis | Everolimus | Trametinib | BRAF | melanoma cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry
by Balakirouchenane, David and Khoudour, Nihel and Guégan, Sarah and Kramkimel, Nora and Franck, Nathalie and Rodier, Thomas and Goldwasser, François and Dupin, Nicolas and Aractingi, Selim and Vidal, Michel and Blanchet, Benoit
Journal of pharmaceutical and biomedical analysis, ISSN 0731-7085, 01/2021, Volume 193, pp. 113718 - 113718
Therapeutic drug monitoring | Dabrafenib | Hydroxy-dabrafenib | LC–MS/MS | Trametinib | Melanoma | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice
by Brown, Carolyn N and Atwood, Daniel J and Pokhrel, Deepak and Ravichandran, Kameswaran and Holditch, Sara J and Saxena, Sanskriti and Miyazaki, Makoto and Nemenoff, Raphael and Weiser-Evans, Mary C.M and Ljubanovic, Danica Galesic and Joy, Melanie S and Edelstein, Charles L
Cellular signalling, ISSN 0898-6568, 07/2020, Volume 71, pp. 109605 - 109605
Cisplatin | Trametinib | AKI | Cancer | ERK | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
by Le Calvez, Baptiste and Le Bris, Yannick and Herbreteau, Guillaume and Jamet, Bastien and Bossard, Céline and Tessoulin, Benoit and Gastinne, Thomas and Mahé, Béatrice and Dubruille, Viviane and Blin, Nicolas and Antier, Chloé and Theisen, Olivier and Kraeber‐Bodéré, Françoise and Le Gouill, Steven and Béné, Marie C and Moreau, Philippe and Touzeau, Cyrille
EJHaem, ISSN 2688-6146, 07/2020, Volume 1, Issue 1, pp. 318 - 322
trametinib | multiple myeloma | BRAF | RAS | dabrafenib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
by Long, G. V and Flaherty, K. T and Stroyakovskiy, D and Gogas, H and Levchenko, E and de Braud, F and Larkin, J and Garbe, C and Jouary, T and Hauschild, A and Chiarion-Sileni, V and Lebbe, C and Mandala, M and Millward, M and Arance, A and Bondarenko, I and Haanen, J. B. A. G and Hansson, J and Utikal, J and Ferraresi, V and Mohr, P and Probachai, V and Schadendorf, D and Nathan, P and Robert, C and Ribas, A and Davies, M. A and Lane, S. R and Legos, J. J and Mookerjee, B and Grob, J. -J
Annals of oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | trametinib | durable outcomes | metastatic | melanoma | BRAF | Original | dabrafenib | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy
by Mormando, Marilda and Puliani, Giulia and Barnabei, Agnese and Lauretta, Rosa and Bianchini, Marta and Chiefari, Alfonsina and Russillo, Michelangelo and Cognetti, Francesco and Romano, Luisa and Appetecchia, Marialuisa
Frontiers in endocrinology (Lausanne), ISSN 1664-2392, 07/2020, Volume 11
Melanoma | Metastasis | pituitary melanoma metastasis | pituitary | trametinib | melanoma | therapy | dabrafenib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia
by Laurent, Anouchka P and Siret, Aurélie and Ignacimouttou, Cathy and Panchal, Kunjal and Diop, M'Boyba and Jenni, Silvia and Tsai, Yi-Chien and Roos-Weil, Damien and Aid, Zakia and Prade, Nais and Lagarde, Stephanie and Plassard, Damien and Pierron, Gaelle and Daudigeos, Estelle and Lecluse, Yann and Droin, Nathalie and Bornhauser, Beat C and Cheung, Laurence C and Crispino, John D and Gaudry, Muriel and Bernard, Olivier A and Macintyre, Elizabeth and Barin Bonnigal, Carole and Kotecha, Rishi S and Geoerger, Birgit and Ballerini, Paola and Bourquin, Jean-Pierre and Delabesse, Eric and Mercher, Thomas and Malinge, Sebastien
Clinical cancer research, ISSN 1078-0432, 07/2020, Volume 26, Issue 13, pp. 3307 - 3318
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus | trametinib | leukemia | oncogenic cooperation | Down syndrome | MAPK | RAS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
by Wu, Christina and Williams, Terence M and Robb, Ryan and Webb, Amy and Wei, Lai and Chen, Wei and Mikhail, Sameh and Ciombor, Kristen K and Cardin, Dana B and Timmers, Cynthia and Krishna, Somashekar G and Arnold, Mark and Harzman, Alan and Abdel-Misih, Sherif and Roychowdhury, Sameek and Bekaii-Saab, Tanios and Wuthrick, Evan
Clinical cancer research, ISSN 1078-0432, 07/2020, Volume 26, Issue 13, pp. 3117 - 3125
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus | trametinib | radiation | rectal cancer | MEK inhibitor | fluorouracil | chemotherapy | 5-FU
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text A combinatorial strategy for overcoming primary and acquired resistance of MEK inhibition in colorectal cancer
by Chen, Junjun and Dai, Jie and Kang, Zhiming and Yang, Ting and Zhao, Qi and Zheng, Jinxiu and Zhang, Xinxin and Zhang, Jisheng and Xu, Jun and Sun, Gongqin and Yang, Lijun and Yang, Tao
Experimental cell research, ISSN 0014-4827, 08/2020, Volume 393, Issue 1, pp. 112060 - 112060
Targeted therapy resistance | Combination therapy | Trametinib | Colorectal cancer | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children
by Kinsler, Veronica A and O'Hare, Patricia and Jacques, Thomas and Hargrave, Darren and Slater, Olga
British journal of cancer, ISSN 0007-0920, 04/2017, Volume 116, Issue 8, pp. 990 - 993
Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Prognosis | Skin Neoplasms - drug therapy | Membrane Proteins - genetics | Central Nervous System Neoplasms - genetics | Humans | Pyrimidinones - therapeutic use | Child, Preschool | Infant | Male | Melanoma - pathology | Mutation - genetics | Central Nervous System Neoplasms - pathology | GTP Phosphohydrolases - genetics | Melanoma - genetics | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Skin Neoplasms - genetics | Female | Pyridones - therapeutic use | Central Nervous System Neoplasms - drug therapy | Index Medicus | trametinib | congenital melanocytic naevus | NRAS | melanoma | CNS | MEK inhibitor | Clinical Study | paediatric
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
by Urbonas, V and Schadendorf, D and Zimmer, L and Danson, S and Marshall, E and Corrie, P and Wheater, M and Plummer, E and Mauch, C and Scudder, C and Goff, M and Love, S B and Mohammed, S B and Middleton, M R
Annals of oncology, ISSN 0923-7534, 02/2019, Volume 30, Issue 2, pp. 317 - 324
Phase II | Pazopanib | Trametinib | Braf wild-type | Melanoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Survival Rate | Melanoma - pathology | Pyridones - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Pyrimidinones - administration & dosage | Mutation | Paclitaxel - administration & dosage | Sulfonamides - administration & dosage | Index Medicus | trametinib | phase II | melanoma | BRAF wild-type | pazopanib | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
by Odogwu, Lauretta and Mathieu, Luckson and Blumenthal, Gideon and Larkins, Erin and Goldberg, Kirsten B and Griffin, Norma and Bijwaard, Karen and Lee, Eunice Y and Philip, Reena and Jiang, Xiaoping and Rodriguez, Lisa and McKee, Amy E and Keegan, Patricia and Pazdur, Richard
The oncologist (Dayton, Ohio), ISSN 1083-7159, 06/2018, Volume 23, Issue 6, pp. 740 - 745
BRAF V600E | Next‐generation sequencing | Dabrafenib | Non‐small cell lung adenocarcinoma | Companion diagnostic | Trametinib | BRAF mutation | Next-generation sequencing | Non-small cell lung adenocarcinoma | Life Sciences & Biomedicine | Oncology | Science & Technology | 23 | FDA | 14 | Regulatory Issues
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights